MedTrace Logo

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

NCT06369935 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2024-04-17

No results posted yet for this study

Summary

This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data

Conditions

Interventions

DRUG

Equecabtagene Autoleucel

Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Jin Lu · Peking University People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2026-08-20
Completion
2027-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06369935 on ClinicalTrials.gov